[go: up one dir, main page]

CU23269A3 - Bromhidrato de eletriptan monohidratado - Google Patents

Bromhidrato de eletriptan monohidratado

Info

Publication number
CU23269A3
CU23269A3 CU20010065A CU20010065A CU23269A3 CU 23269 A3 CU23269 A3 CU 23269A3 CU 20010065 A CU20010065 A CU 20010065A CU 20010065 A CU20010065 A CU 20010065A CU 23269 A3 CU23269 A3 CU 23269A3
Authority
CU
Cuba
Prior art keywords
eletriptan
monohidrated
bromhydrate
monohydrate
formula
Prior art date
Application number
CU20010065A
Other languages
English (en)
Inventor
Ronald James Ogilvie
Christopher Ian Dallman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU23269A3 publication Critical patent/CU23269A3/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)

Abstract

La presente invencion proporciona bromhidrato de eletriptAn monohidratado de formula ( I ) : ESPACIO PARA FORMULA. junto con procedimientos para preparar dicho monohidrato, usos del mismo y composiciones que lo contienen.
CU20010065A 1998-11-27 2001-03-13 Bromhidrato de eletriptan monohidratado CU23269A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
CU23269A3 true CU23269A3 (es) 2008-04-09

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20010065A CU23269A3 (es) 1998-11-27 2001-03-13 Bromhidrato de eletriptan monohidratado

Country Status (53)

Country Link
US (2) US20020013358A1 (es)
EP (1) EP1135381B1 (es)
JP (1) JP3777094B2 (es)
KR (1) KR100413739B1 (es)
CN (1) CN1131860C (es)
AP (1) AP2001002149A0 (es)
AR (1) AR024232A1 (es)
AT (1) ATE273300T1 (es)
AU (1) AU754731B2 (es)
BG (1) BG64706B1 (es)
BR (1) BR9915692A (es)
CA (1) CA2352392C (es)
CO (1) CO5150178A1 (es)
CR (1) CR6325A (es)
CU (1) CU23269A3 (es)
CZ (1) CZ295472B6 (es)
DE (1) DE69919388T2 (es)
DK (1) DK1135381T3 (es)
DZ (1) DZ2948A1 (es)
EA (1) EA003551B1 (es)
EE (1) EE04914B1 (es)
ES (1) ES2224701T3 (es)
GB (1) GB9825988D0 (es)
GC (1) GC0000113A (es)
GE (1) GEP20043183B (es)
GT (1) GT199900202A (es)
HK (1) HK1042898B (es)
HN (1) HN1999000196A (es)
HR (1) HRP20010398B1 (es)
HU (1) HUP0105308A3 (es)
ID (1) ID28802A (es)
IL (1) IL141663A (es)
IS (1) IS2238B (es)
MA (1) MA26708A1 (es)
MY (1) MY124078A (es)
NO (1) NO320798B1 (es)
NZ (1) NZ510055A (es)
OA (1) OA11671A (es)
PA (1) PA8485701A1 (es)
PE (1) PE20001299A1 (es)
PL (1) PL194503B1 (es)
PT (1) PT1135381E (es)
RS (1) RS50002B (es)
SI (1) SI1135381T1 (es)
SK (1) SK285774B6 (es)
SV (1) SV1999000204A (es)
TN (1) TNSN99221A1 (es)
TR (1) TR200101493T2 (es)
TW (1) TWI246512B (es)
UA (1) UA68402C2 (es)
UY (2) UY25823A1 (es)
WO (1) WO2000032589A1 (es)
ZA (1) ZA200102681B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
CA2521902A1 (en) 2003-04-11 2004-10-21 Pfizer Inc. Pharmaceutical combination comprising eletriptan and sodium bicarbonate
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP2046777A2 (en) * 2007-05-01 2009-04-15 Plus Chemicals B.V. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) * 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
DK0592438T5 (da) 1990-10-15 1999-12-06 Pfizer Inc. Indolderivater
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
PT999841E (pt) 1997-07-03 2002-02-28 Pfizer Composicoes farmaceuticas contendo hemissulfato de eletriptano

Also Published As

Publication number Publication date
BG105539A (en) 2001-12-29
EP1135381A1 (en) 2001-09-26
ID28802A (id) 2001-07-05
HRP20010398B1 (en) 2004-12-31
US7238723B2 (en) 2007-07-03
SV1999000204A (es) 2000-10-16
DZ2948A1 (fr) 2004-03-15
PE20001299A1 (es) 2000-12-01
YU18801A (sh) 2003-07-07
SK6992001A3 (en) 2002-01-07
UY25825A1 (es) 2000-08-21
JP2002531449A (ja) 2002-09-24
CN1131860C (zh) 2003-12-24
CA2352392A1 (en) 2000-06-08
CR6325A (es) 2008-07-02
DE69919388D1 (de) 2004-09-16
IS2238B (is) 2007-05-15
NZ510055A (en) 2004-11-26
KR20010080594A (ko) 2001-08-22
CN1328554A (zh) 2001-12-26
CA2352392C (en) 2006-01-24
SI1135381T1 (en) 2004-10-31
PL194503B1 (pl) 2007-06-29
IS5868A (is) 2001-02-27
CO5150178A1 (es) 2002-04-29
EA003551B1 (ru) 2003-06-26
DE69919388T2 (de) 2005-09-29
IL141663A (en) 2004-05-12
GB9825988D0 (en) 1999-01-20
TR200101493T2 (tr) 2002-02-21
US20020013358A1 (en) 2002-01-31
HRP20010398A2 (en) 2002-06-30
EE04914B1 (et) 2007-10-15
CZ295472B6 (cs) 2005-08-17
PA8485701A1 (es) 2000-09-29
HUP0105308A3 (en) 2003-01-28
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
AP2001002149A0 (en) 2001-06-30
GEP20043183B (en) 2004-02-25
ATE273300T1 (de) 2004-08-15
DK1135381T3 (da) 2004-11-15
IL141663A0 (en) 2002-03-10
MY124078A (en) 2006-06-30
AU754731B2 (en) 2002-11-21
GT199900202A (es) 2001-05-19
TWI246512B (en) 2006-01-01
EE200100285A (et) 2002-08-15
AR024232A1 (es) 2002-09-25
NO320798B1 (no) 2006-01-30
UA68402C2 (en) 2004-08-16
HK1042898B (zh) 2004-10-08
KR100413739B1 (ko) 2004-01-03
PT1135381E (pt) 2004-10-29
JP3777094B2 (ja) 2006-05-24
WO2000032589A1 (en) 2000-06-08
US20050131237A1 (en) 2005-06-16
BG64706B1 (bg) 2005-12-30
HN1999000196A (es) 2005-11-26
SK285774B6 (sk) 2007-08-02
ES2224701T3 (es) 2005-03-01
RS50002B (sr) 2008-09-29
HK1042898A1 (en) 2002-08-30
AU6225399A (en) 2000-06-19
PL347928A1 (en) 2002-04-22
HUP0105308A2 (hu) 2002-05-29
NO20012584L (no) 2001-07-27
TNSN99221A1 (fr) 2005-11-10
BR9915692A (pt) 2001-08-14
OA11671A (en) 2005-01-12
UY25823A1 (es) 2001-08-27
ZA200102681B (en) 2002-07-02
NO20012584D0 (no) 2001-05-25
CZ20011839A3 (cs) 2001-10-17
MA26708A1 (fr) 2004-12-20
EA200100297A1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
BR9902086A (pt) Formulações farmacêuticas.
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
PA8561301A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
DK1413582T3 (da) Dimere pyrrolobenzodiazepiner
AR028948A1 (es) Compuestos novedosos
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
DE60007095D1 (de) Calanolide zur hemmung von btk
CU23269A3 (es) Bromhidrato de eletriptan monohidratado
AU2003228770A8 (en) Substituted pyrazolopyrimidines
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
AR024138A1 (es) Inhibidores de la proliferacion celular
ES2243579T3 (es) Derivados de pirazolopirideno.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
GT199900214A (es) Combinacion de cerivastatina y fibratos.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
CO4940435A1 (es) Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6- (ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol o un solvato del mismo
ES2174297T3 (es) Nuevos derivados de piranosidos.
DE60201074D1 (en) Pyrazolopyridinderivate
DK1073447T3 (da) N1-modificerede glycopeptider